UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-K ____________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 ______________________ ...

Varex Imaging Corporation (NASDAQ:VREX) Q4 2022 Earnings Conference Call November 15, 2022 5:00 PM ET Company Participants Christopher Belfiore - Director of Investor Relations Sunny Sanyal - President & Chief Executive Officer Sam Maheshwari - Chief Financial Officer Conference Call Participants Larry Solow - CJS Suraj Kalia - Oppenheimer Anthony Petrone - Mizuho Group Jim Sidoti - Sidoti & Company Operator Hello and welcome to the Varex Fourth Quarter Fiscal Year 2022 Earnings Call. At this time, all part ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-Q ____________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 1, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 _____________ ...

Varex Imaging Corporation (NASDAQ:VREX) Q3 2022 Results Conference Call August 2, 2022 5:00 PM ET Company Participants Christopher Belfiore - Director of Investor Relations Sunny Sanyal - President and Chief Executive Officer Shubham Maheshwari - Chief Financial Officer Conference Call Participants Larry Solow - CJS Securities James Sidoti - Sidoiti & Company Suraj Kalia - Oppenheimer& Co Operator Greetings. Welcome to the Varex Third Quarter Fiscal Year 2022 Earnings Call. At this time, all participants ar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-Q ____________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 1, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 ____________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-Q ____________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 ________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-K ____________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended October 1, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 VAREX IMAGING CORPORATION ...

Varex Imaging Corporation (NASDAQ:VREX) Q4 2021 Earnings Conference Call November 16, 2021 5:00 PM ET Company Participants Chris Belfiore - Director of Investor Relations Sunny Sanyal - President and CEO Sam Maheshwari - CFO Conference Call Participants Frank Pinal - Jefferies Larry Solow - CJS Securities Jim Sidoti - Sidoti and Company Suraj Kalia - Oppenheimer Operator Greetings. Welcome to the Varex Fourth Quarter 2021 Earnings Conference Call. At this time, all participants are in listen only mode. A qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-Q ____________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 2, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 _____________ ...

Financial Data and Key Metrics Changes - Revenues reached $211 million, a 4% sequential increase and a 23% year-over-year increase, driven by strong demand in both Medical and Industrial segments [9][10] - Non-GAAP gross margin improved to 36%, while non-GAAP operating margin increased to 14% of revenues, resulting in non-GAAP EPS of $0.40, exceeding guidance [11][29] - GAAP gross margin was 35%, up over 300 basis points sequentially, with operating income increasing by $10 million compared to the previous quarter [31][32] Business Line Data and Key Metrics Changes - Medical segment revenues increased 7% sequentially and 22% year-over-year, with strong demand for CT tubes and other modalities returning to pre-COVID levels [10][11] - Industrial segment revenues decreased 6% sequentially but increased 31% year-over-year, attributed to timing of sales [14][29] Market Data and Key Metrics Changes - Revenue levels in the Americas decreased by 7% sequentially, while EMEA grew by 13% and APAC grew by 6% [30] - China is identified as a significant growth opportunity, with expected revenues exceeding $100 million by fiscal year-end 2021, representing 25% to 30% year-over-year growth [18][19] Company Strategy and Development Direction - The company is focusing on establishing relationships with local OEMs in China to drive growth, with nine out of twelve CT projects already brought to market [16][22] - New product development efforts include the launch of the LUMEN 4336W detector and advancements in nanotube technology [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong demand for CT tubes and other medical modalities, indicating that the demand is not solely a catch-up from the pandemic [98][101] - Supply chain challenges are acknowledged, particularly regarding raw materials and semiconductors, but management believes they are managing these issues effectively [26][50] Other Important Information - R&D spending was $19 million, or 9% of revenues, reflecting continued prioritization towards innovation and new product development [35][60] - Cash flow from operations improved to $22 million, with cash on hand increasing to $128 million [40][41] Q&A Session Summary Question: Can you provide insights on the demand dynamics for CT tubes in China and supply chain issues? - Management indicated strong demand for CT tubes and acknowledged supply chain issues related to commodities and semiconductors, but they are not currently demand constrained [49][50][51] Question: How much of the gross margin benefit was from sales volume versus cost savings? - Management confirmed that gross margin benefits were primarily driven by higher sales volume and successful cost reduction initiatives, particularly from the migration of manufacturing [56][57] Question: What is the outlook for revenue guidance in Q4? - Management provided guidance for Q4 revenues between $205 million and $225 million, indicating confidence in demand despite potential supply chain constraints [45][121] Question: How is the company performing in comparison to local and global OEMs in China? - Management stated that local OEMs are gaining market share in CTs, and the company is also gaining share in tubes, indicating a positive trend [73][74] Question: What are the expectations for new product contributions to revenue growth? - Management expects future growth from new products developed through increased R&D investments, which have been accelerated due to prior tax savings [82][86]